RLAY Reports $12M Revenue, $0.08 EPS, +120% YoY, Announces $200M Buyback, Phase 3 Breast Cancer Trial 2027
Relay Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $14.05
-14% in 7d after detection
Post-detection moves
1h
—
1d
-13%
3d
-13%
7d
-14%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS